Acylated iridoids and rhamnopyranoses from premna odorata (lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer

Abeer H. Elmaidomy, Mohamed M. Mohyeldin, Mostafa M. Ibrahim, Hossam Mokhtar Hassan, Elham Amin, Mostafa E. Rateb, Mona H. Hetta, Khalid A. El Sayed

Research output: Contribution to journalArticle

73 Downloads (Pure)

Abstract

Phytochemical investigation of Premna odorata Blanco, Lamiaceae, leaves afforded three new acylated iridoid glycosides 1-3 and two new acylated rhamnopyranoses 9 and 10, in addition to ten known compounds. The structures of the new compounds were confirmed using extensive 1D and 2D NMR analysis. Molecular modeling study suggested the potential of the acylated rhamnopyranoses to bind at the c-Met kinase domain. Cell-free Z'-LYTE™ assay testing revealed the good c-Met phosphorylation inhibitory activity of 9, followed by 8, and 10, with IC50 values of 2.5, 6.9, and 12.7 μM, respectively. The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay testing against the human c-Met expressing highly invasive MDA-MB-231 suggested compound 9 as the most active with IC50 value of 13.3 μM. Testing of compound 9 against multiple phenotypic breast cancer cell lines including MCF-7, BT-474 cells, and MDA-MB-468 proved enhanced activity against the highly c-Met expressing triple-negative breast cancer cell lines. Acylated rhamnopyranoses are potential novel c-Met inhibitors appropriate for future optimizations to control c-Met-dependent breast malignancies. Copyright © 2017 John Wiley & Sons, Ltd.

Original languageEnglish
Pages (from-to)1546-1556
Number of pages11
JournalPhytotherapy research : PTR
Volume31
Issue number10
Early online date15 Aug 2017
DOIs
Publication statusE-pub ahead of print - 15 Aug 2017

Fingerprint

Iridoids
Lamiaceae
Epithelial-Mesenchymal Transition
Inhibitory Concentration 50
Iridoid Glycosides
Triple Negative Breast Neoplasms
Breast Neoplasms
Cell Line
Phytochemicals
Breast
Phosphotransferases
Phosphorylation
Cell Proliferation
Neoplasms

Cite this

Elmaidomy, Abeer H. ; Mohyeldin, Mohamed M. ; Ibrahim, Mostafa M. ; Mokhtar Hassan, Hossam ; Amin, Elham ; Rateb, Mostafa E. ; Hetta, Mona H. ; El Sayed, Khalid A. / Acylated iridoids and rhamnopyranoses from premna odorata (lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer. In: Phytotherapy research : PTR. 2017 ; Vol. 31, No. 10. pp. 1546-1556.
@article{bf7d2733f60644158523c7c6e2706156,
title = "Acylated iridoids and rhamnopyranoses from premna odorata (lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer",
abstract = "Phytochemical investigation of Premna odorata Blanco, Lamiaceae, leaves afforded three new acylated iridoid glycosides 1-3 and two new acylated rhamnopyranoses 9 and 10, in addition to ten known compounds. The structures of the new compounds were confirmed using extensive 1D and 2D NMR analysis. Molecular modeling study suggested the potential of the acylated rhamnopyranoses to bind at the c-Met kinase domain. Cell-free Z'-LYTE™ assay testing revealed the good c-Met phosphorylation inhibitory activity of 9, followed by 8, and 10, with IC50 values of 2.5, 6.9, and 12.7 μM, respectively. The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay testing against the human c-Met expressing highly invasive MDA-MB-231 suggested compound 9 as the most active with IC50 value of 13.3 μM. Testing of compound 9 against multiple phenotypic breast cancer cell lines including MCF-7, BT-474 cells, and MDA-MB-468 proved enhanced activity against the highly c-Met expressing triple-negative breast cancer cell lines. Acylated rhamnopyranoses are potential novel c-Met inhibitors appropriate for future optimizations to control c-Met-dependent breast malignancies. Copyright {\circledC} 2017 John Wiley & Sons, Ltd.",
author = "Elmaidomy, {Abeer H.} and Mohyeldin, {Mohamed M.} and Ibrahim, {Mostafa M.} and {Mokhtar Hassan}, Hossam and Elham Amin and Rateb, {Mostafa E.} and Hetta, {Mona H.} and {El Sayed}, {Khalid A.}",
note = "12 months embargo",
year = "2017",
month = "8",
day = "15",
doi = "10.1002/ptr.5882",
language = "English",
volume = "31",
pages = "1546--1556",
journal = "Phytotherapy research : PTR",
issn = "0951-418X",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

Acylated iridoids and rhamnopyranoses from premna odorata (lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer. / Elmaidomy, Abeer H.; Mohyeldin, Mohamed M.; Ibrahim, Mostafa M.; Mokhtar Hassan, Hossam; Amin, Elham; Rateb, Mostafa E.; Hetta, Mona H.; El Sayed, Khalid A.

In: Phytotherapy research : PTR, Vol. 31, No. 10, 15.08.2017, p. 1546-1556.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Acylated iridoids and rhamnopyranoses from premna odorata (lamiaceae) as novel mesenchymal-epithelial transition factor receptor inhibitors for the control of breast cancer

AU - Elmaidomy, Abeer H.

AU - Mohyeldin, Mohamed M.

AU - Ibrahim, Mostafa M.

AU - Mokhtar Hassan, Hossam

AU - Amin, Elham

AU - Rateb, Mostafa E.

AU - Hetta, Mona H.

AU - El Sayed, Khalid A.

N1 - 12 months embargo

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Phytochemical investigation of Premna odorata Blanco, Lamiaceae, leaves afforded three new acylated iridoid glycosides 1-3 and two new acylated rhamnopyranoses 9 and 10, in addition to ten known compounds. The structures of the new compounds were confirmed using extensive 1D and 2D NMR analysis. Molecular modeling study suggested the potential of the acylated rhamnopyranoses to bind at the c-Met kinase domain. Cell-free Z'-LYTE™ assay testing revealed the good c-Met phosphorylation inhibitory activity of 9, followed by 8, and 10, with IC50 values of 2.5, 6.9, and 12.7 μM, respectively. The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay testing against the human c-Met expressing highly invasive MDA-MB-231 suggested compound 9 as the most active with IC50 value of 13.3 μM. Testing of compound 9 against multiple phenotypic breast cancer cell lines including MCF-7, BT-474 cells, and MDA-MB-468 proved enhanced activity against the highly c-Met expressing triple-negative breast cancer cell lines. Acylated rhamnopyranoses are potential novel c-Met inhibitors appropriate for future optimizations to control c-Met-dependent breast malignancies. Copyright © 2017 John Wiley & Sons, Ltd.

AB - Phytochemical investigation of Premna odorata Blanco, Lamiaceae, leaves afforded three new acylated iridoid glycosides 1-3 and two new acylated rhamnopyranoses 9 and 10, in addition to ten known compounds. The structures of the new compounds were confirmed using extensive 1D and 2D NMR analysis. Molecular modeling study suggested the potential of the acylated rhamnopyranoses to bind at the c-Met kinase domain. Cell-free Z'-LYTE™ assay testing revealed the good c-Met phosphorylation inhibitory activity of 9, followed by 8, and 10, with IC50 values of 2.5, 6.9, and 12.7 μM, respectively. The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay testing against the human c-Met expressing highly invasive MDA-MB-231 suggested compound 9 as the most active with IC50 value of 13.3 μM. Testing of compound 9 against multiple phenotypic breast cancer cell lines including MCF-7, BT-474 cells, and MDA-MB-468 proved enhanced activity against the highly c-Met expressing triple-negative breast cancer cell lines. Acylated rhamnopyranoses are potential novel c-Met inhibitors appropriate for future optimizations to control c-Met-dependent breast malignancies. Copyright © 2017 John Wiley & Sons, Ltd.

U2 - 10.1002/ptr.5882

DO - 10.1002/ptr.5882

M3 - Article

VL - 31

SP - 1546

EP - 1556

JO - Phytotherapy research : PTR

JF - Phytotherapy research : PTR

SN - 0951-418X

IS - 10

ER -